Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Report

Global and Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Professional Survey Report 2019

  • POSTDATE：Nov 15, 2019
  • PAGES：197
  • REPORT CODE：GMM381451
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug market was valued at XX.0 million US$ in 2018, with the CAGR of 6.4%, this market is estimated to reach USD XX.0 million US$ in 2026.

    This report mainly elaborates on the segmentation, end-user, size, share, trend, future demand and leading players with respect to the Global and Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug market. Describe product range of Non-Alcoholic Fatty Liver Disease (Nafld) Drug, market overview, market opportunities, market drivers, limitations, PEST and SWOT analysis. Introducing market share, production, consumption, revenue, and growth of Global major regions from 2014-2019 and forecast to 2026.

    The report also provides a detailed analysis of the Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug market from 2014 to 2026 based on the product type and end-user. It provides a detailed overview of the market of the top 16 countries of Europe along with top companies' data analysis and product introductions of Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug market.

     

    By Player

    • Verva Pharmaceuticals

    • Phenex Pharmaceuticals

    • Tobira Therapeutics

    • Conatus Pharmaceuticals

    • Raptor Pharmaceuticals

    • Kyorin Pharmaceutical

    • Metabolic Solutions Development

    • Novartis AG

    • Galmed International

    • Zafgen

    • Daewoong Pharmaceutical

    • TCM Biotech International

    By Type

    • Type 1

    • Type 2

    • Type 3

    By End-User

    • End-User 1

    • End-User 2

    • End-User 3

    By Region

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Belgium

    • Poland

    • Russia

    • Turkey

    • Netherlands

    • Portugal

    • Denmark

    • Finland

    • Iceland

    • Norway

    • Sweden

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia and New Zealand

    • ASEAN Countries (Indonesia, Thailand, Malaysia, Singapore, Philippines, Vietnam, Others)

    Latin America, Middle East & Africa

    • GCC Countries (Saudi Arabia, United Arab Emirates, Qatar, Others)

    • Brazil

    • Nigeria

    • South Africa

    • Argentina

    • Others

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market

    • 1.3 Market Segment by Type

      • 1.3.1 Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 1 from 2014 to 2026

      • 1.3.2 Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 2 from 2014 to 2026

      • 1.3.3 Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 3 from 2014 to 2026

    • 1.4 Market Segment by Application

      • 1.4.1 Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 1 from 2014 to 2026

      • 1.4.2 Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 2 from 2014 to 2026

      • 1.4.3 Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 3 from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 North America Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 Asia-Pacific Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 LAMEA Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Major Types

      • 3.4.1 Market Size and Growth Rate of Type 1

      • 3.4.2 Market Size and Growth Rate of Type 2

      • 3.4.3 Market Size and Growth Rate of Type 3

    4 Segmentation of Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Non-Alcoholic Fatty Liver Disease (Nafld) Drug for End-User 1

      • 4.4.2 Market Size and Growth Rate of Non-Alcoholic Fatty Liver Disease (Nafld) Drug for End-User 2

      • 4.4.3 Market Size and Growth Rate of Non-Alcoholic Fatty Liver Disease (Nafld) Drug for End-User 3

    5 Market Analysis by Major Regions

    • 5.1 Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production Analysis by Top Regions

    • 5.2 Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Analysis by Top Regions

    • 5.3 Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 North America Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.2 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.3 Asia Pacific Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.4 LAMEA Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    6 Product Circulation of Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market among Top Countries

    • 6.1 Top 5 Export Countries in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. North America Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 7.1 North America Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Top Countries

      • 7.1.1 United States Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 7.1.2 Canada Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 7.1.3 Mexico Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

    8. Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 8.1 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 8.2 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    • 8.3 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Top Countries

      • 8.3.1 Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.2 UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.3 France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.4 Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.5 Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.6 Belgium Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.7 Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.8 Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.9 Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.10 Netherlands Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.11 Portugal Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.12 Denmark Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.13 Finland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.14 Iceland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.15 Norway Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 8.3.16 Sweden Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

    • 8.4 Top 3 Players Profiles in Europe

    9 Asia Pacific Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 9.1 Asia Pacific Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Top Countries

      • 9.1.1 China Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 9.1.2 Japan Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 9.1.3 Australia and New Zealand (ANZ) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 9.1.4 India Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 9.1.5 ASEAN Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 9.1.6 South Korea Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

    10 LAMEA Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 10.1 LAMEA Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Top Countries

      • 10.1.1 GCC Countries Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 10.1.2 Brazil Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 10.1.3 North Africa Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 10.1.4 South Africa Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 10.1.5 Argentina Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

    11 Major Players Profiles

    • 11.1 Verva Pharmaceuticals

      • 11.1.1 Verva Pharmaceuticals Company Profile and Development Status

      • 11.1.2 Market Performance

      • 11.1.3 Product and Service Introduction

    • 11.2 Phenex Pharmaceuticals

      • 11.2.1 Phenex Pharmaceuticals Company Profile and Development Status

      • 11.2.2 Market Performance

      • 11.2.3 Product and Service Introduction

    • 11.3 Tobira Therapeutics

      • 11.3.1 Tobira Therapeutics Company Profile and Development Status

      • 11.3.2 Market Performance

      • 11.3.3 Product and Service Introduction

    • 11.4 Conatus Pharmaceuticals

      • 11.4.1 Conatus Pharmaceuticals Company Profile and Development Status

      • 11.4.2 Market Performance

      • 11.4.3 Product and Service Introduction

    • 11.5 Raptor Pharmaceuticals

      • 11.5.1 Raptor Pharmaceuticals Company Profile and Development Status

      • 11.5.2 Market Performance

      • 11.5.3 Product and Service Introduction

    • 11.6 Kyorin Pharmaceutical

      • 11.6.1 Kyorin Pharmaceutical Company Profile and Development Status

      • 11.6.2 Market Performance

      • 11.6.3 Product and Service Introduction

    • 11.7 Metabolic Solutions Development

      • 11.7.1 Metabolic Solutions Development Company Profile and Development Status

      • 11.7.2 Market Performance

      • 11.7.3 Product and Service Introduction

    • 11.8 Novartis AG

      • 11.8.1 Novartis AG Company Profile and Development Status

      • 11.8.2 Market Performance

      • 11.8.3 Product and Service Introduction

    • 11.9 Galmed International

      • 11.9.1 Galmed International Company Profile and Development Status

      • 11.9.2 Market Performance

      • 11.9.3 Product and Service Introduction

    • 11.10 Zafgen

      • 11.10.1 Zafgen Company Profile and Development Status

      • 11.10.2 Market Performance

      • 11.10.3 Product and Service Introduction

    • 11.11 Daewoong Pharmaceutical

      • 11.11.1 Daewoong Pharmaceutical Company Profile and Development Status

      • 11.11.2 Market Performance

      • 11.11.3 Product and Service Introduction

    • 11.12 TCM Biotech International

      • 11.12.1 TCM Biotech International Company Profile and Development Status

      • 11.12.2 Market Performance

      • 11.12.3 Product and Service Introduction

     

    The List of Tables and Figures (Totals 100 Figures and 125 Tables)

    • Figure Product Picture

    • Figure Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 1 from 2014 to 2026

    • Figure Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 2 from 2014 to 2026

    • Figure Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 3 from 2014 to 2026

    • Figure Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 1 from 2014 to 2026

    • Figure Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 2 from 2014 to 2026

    • Figure Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 3 from 2014 to 2026

    • Figure North America Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure United States Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Asia-Pacific Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure China Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Japan Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Australia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure India Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure ASEAN Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure South Korea Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure LAMEA Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure GCC Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Brazil Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure North Africa Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure South Africa Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Argentina Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Non-Alcoholic Fatty Liver Disease (Nafld) Drug Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Non-Alcoholic Fatty Liver Disease (Nafld) Drug

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Different Types from 2014 to 2026

    • Table Consumption Share of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Type 1

    • Figure Market Size and Growth Rate of Type 2

    • Figure Market Size and Growth Rate of Type 3

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Different End-Users from 2014 to 2026

    • Table Consumption Share of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of End-User 1

    • Figure Market Size and Growth Rate of End-User 2

    • Figure Market Size and Growth Rate of End-User 3

    • Table Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production by Major Regions

    • Table Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production Share by Major Regions

    • Table Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Major Regions

    • Table Global Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Regions

    • Table North America Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Asia Pacific Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table LAMEA Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table North America Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Major Countries from 2014 to 2026

    • Table North America Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure North America Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Countries in 2014

    • Figure North America Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Countries in 2018

    • Figure North America Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Countries in 2026

    • Figure United States Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Canada Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Mexico Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Major Countries from 2014 to 2026

    • Table Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Nordic Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Belgium Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Portugal Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Denmark Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Asia Pacific Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Major Countries from 2014 to 2026

    • Table Asia Pacific Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure China Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Japan Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Australia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure India Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure ASEAN Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure South Korea Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Latin America, Middle East & Africa Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Major Countries from 2014 to 2026

    • Table Latin America, Middle East & Africa Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure GCC Countries Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Brazil Countries Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure North Africa Countries Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure South Africa Countries Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Argentina Countries Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Verva Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Verva Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Verva Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Verva Pharmaceuticals

    • Table Product and Service Introduction of Verva Pharmaceuticals

    • Table Company Profile and Development Status of Phenex Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Phenex Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Phenex Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Phenex Pharmaceuticals

    • Table Product and Service Introduction of Phenex Pharmaceuticals

    • Table Company Profile and Development Status of Tobira Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Tobira Therapeutics

    • Figure Sales and Growth Rate Analysis of Tobira Therapeutics

    • Figure Revenue and Market Share Analysis of Tobira Therapeutics

    • Table Product and Service Introduction of Tobira Therapeutics

    • Table Company Profile and Development Status of Conatus Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Conatus Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Conatus Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Conatus Pharmaceuticals

    • Table Product and Service Introduction of Conatus Pharmaceuticals

    • Table Company Profile and Development Status of Raptor Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Raptor Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Raptor Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Raptor Pharmaceuticals

    • Table Product and Service Introduction of Raptor Pharmaceuticals

    • Table Company Profile and Development Status of Kyorin Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Kyorin Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Kyorin Pharmaceutical

    • Figure Revenue and Market Share Analysis of Kyorin Pharmaceutical

    • Table Product and Service Introduction of Kyorin Pharmaceutical

    • Table Company Profile and Development Status of Metabolic Solutions Development

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Metabolic Solutions Development

    • Figure Sales and Growth Rate Analysis of Metabolic Solutions Development

    • Figure Revenue and Market Share Analysis of Metabolic Solutions Development

    • Table Product and Service Introduction of Metabolic Solutions Development

    • Table Company Profile and Development Status of Novartis AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis AG

    • Figure Sales and Growth Rate Analysis of Novartis AG

    • Figure Revenue and Market Share Analysis of Novartis AG

    • Table Product and Service Introduction of Novartis AG

    • Table Company Profile and Development Status of Galmed International

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Galmed International

    • Figure Sales and Growth Rate Analysis of Galmed International

    • Figure Revenue and Market Share Analysis of Galmed International

    • Table Product and Service Introduction of Galmed International

    • Table Company Profile and Development Status of Zafgen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Zafgen

    • Figure Sales and Growth Rate Analysis of Zafgen

    • Figure Revenue and Market Share Analysis of Zafgen

    • Table Product and Service Introduction of Zafgen

    • Table Company Profile and Development Status of Daewoong Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Daewoong Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Daewoong Pharmaceutical

    • Figure Revenue and Market Share Analysis of Daewoong Pharmaceutical

    • Table Product and Service Introduction of Daewoong Pharmaceutical

    • Table Company Profile and Development Status of TCM Biotech International

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of TCM Biotech International

    • Figure Sales and Growth Rate Analysis of TCM Biotech International

    • Figure Revenue and Market Share Analysis of TCM Biotech International

    • Table Product and Service Introduction of TCM Biotech International

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US